Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688580's ROE % is ranked better than 74.06% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs SHSE:688580: 9.92
Nanjing Vishee Medical Technology Co (SHSE:688580) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Nanjing Vishee Medical Technology Co ROE % Related Terms
Nanjing Vishee Medical Technology Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nanjing Vishee Medical Technology Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Vishee Medical Technology Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Vishee Medical Technology Co's ROE % distribution charts can be found below:
* The bar in red indicates where Nanjing Vishee Medical Technology Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Nanjing Vishee Medical Technology Co (SHSE:688580) has a ROE % of 14.28% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nanjing Vishee Medical Technology Co and its competitors. This is near median its historical median of 14.73. Over the past decade, Nanjing Vishee Medical Technology Co's ROE % has ranged from 6.13 to 45.67. According to the industry distribution chart, Nanjing Vishee Medical Technology Co ranks #207 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 25.9%.
Is Nanjing Vishee Medical Technology Co's ROE % too high?
Nanjing Vishee Medical Technology Co's current ROE % of 14.28% is near median its 10-year median of 14.73. Over the past 10 years, this metric has ranged from a low of 6.13 to a high of 45.67. The Medical Devices & Instruments industry median ROE % is 2.51. Nanjing Vishee Medical Technology Co's value of 14.28% is 468.9% above this industry median. Based on the distribution chart, Nanjing Vishee Medical Technology Co ranks #207 out of 798 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nanjing Vishee Medical Technology Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vishee Medical Technology Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Vishee Medical Technology Co ranks #207 out of 798 companies for ROE %. This puts Nanjing Vishee Medical Technology Co in the upper half of its industry. The industry median ROE % is 2.51. Nanjing Vishee Medical Technology Co's value of 14.28% is 468.9% above this benchmark. Historically, Nanjing Vishee Medical Technology Co's own ROE % has ranged from 6.13 to 45.67 over the past decade. While the company's 10-year median is 14.73 vs. the industry median of 2.51, Nanjing Vishee Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.51, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Vishee Medical Technology Co's current ROE % of 14.28% is 468.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nanjing Vishee Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Vishee Medical Technology Co's current ROE % is 14.28%, which is near median its own 10-year median of 14.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vishee Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co (SHSE:688580) is currently considered Fairly Valued. The stock's GF Value™ is ¥54.15, compared to a current price of ¥50.56 — trading 6.6% below its estimated fair value. The current ROE % is 14.28%, which is near median its 10-year median of 14.73 and 468.9% above the Medical Devices & Instruments industry median of 2.51. Nanjing Vishee Medical Technology Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Nanjing Vishee Medical Technology Co (SHSE:688580), the current ROE % is 14.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Vishee Medical Technology Co (SHSE:688580) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co stock appears to be undervalued.
The current stock price of ¥50.56 is trading 6.6% below its estimated GF Value™ of ¥54.15.
GuruFocus considers Nanjing Vishee Medical Technology Co to be Fairly Valued.
Key valuation signals for SHSE:688580:
ROE %: 14.28% (near median its 10-year median of 14.73)
GF Value™: ¥54.15 vs. price of ¥50.56 (6.6% below fair value)
Industry Position: 468.9% above the Medical Devices & Instruments median (#207 of 798)
No single metric tells the full story. See the SHSE:688580 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Vishee Medical Technology Co Business Description
Nanjing Vishee Medical Technology Co Ltd is engaged in production and sales of rehabilitation medical devices. The company's products under Pelvic floor and postpartum rehabilitation include Pelvic floor electromyography biofeedback instrument; Myotrac series biological stimulation feedback instrument; Ruiyi Series Biostimulation Feedback Apparatus; Magneuro Series Magnetic Stimulator; Female psychological rehabilitation; Neonatal electroencephalograph; Consumables; and under Mental rehabilitation include Multi-parameter biofeedback instrument; Group biofeedback; Magneuro Series Magnetic Stimulator; and Cognitive dysfunction treatment software.
89GF Score
Get the complete analysis for SHSE:688580
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688580 has been successfully added to your 
